|
1.
|
|
17 p, 345.4 KB |
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
/
Casali, P.G. (University of Milan) ;
Bielack, Stefan S (Klinikum Stuttgart-Olgahospital) ;
Abecassis, N. (Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE) ;
Aro, H.T. (Turku University Hospital (Turun Yliopistollinen Keskussairaala)) ;
Bauer, S. (University Hospital Essen (Alemanya)) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bonvalot, S. (Institut Curie) ;
Boukovinas, I. (Bioclinic Thessaloniki) ;
Bovee, J.V.M.G. (Leiden University Medical Center) ;
Brennan, B. (Royal Manchester Children's Hospital) ;
Brodowicz, Thomas (Medizinische Universität Wien) ;
Broto, J.M. (Hospital Universitario Virgen Del Rocio-CIBERONC) ;
Brugières, L. (Gustave Roussy Cancer Campus) ;
Buonadonna, A. (Centro di Riferimento Oncologico di Aviano) ;
De Alava, E (Universidad de Sevilla) ;
Dei Tos, A.P. (Ospedale Regionale di Treviso S.Maria di Cà Foncello) ;
Del Muro, X.G. (Integrated Unit ICO Hospitalet) ;
Dileo, P. (University College London Hospitals NHS Trust) ;
Dhooge, C. (Universitair Ziekenhuis Gent) ;
Eriksson, M. (Skåne University Hospital (Suècia)) ;
Fagioli, F. (University of Turin) ;
Fedenko, A. (N. N. Blokhin Russian Cancer Research Center) ;
Ferraresi, V. (Regina Elena National Cancer Institute) ;
Ferrari, A. (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Ferrari, S. (Istituto Ortopedico Rizzoli) ;
Frezza, A.M. (Istituto Nazionale Dei Tumori) ;
Gaspar, N. (Gustave Roussy Cancer Campus) ;
Gasperoni, S. (Azienda Ospedaliera Universitaria Careggi Firenze) ;
Gelderblom, H. (Leiden University Medical Centre) ;
Gil, T. (Institut Jules Bordet) ;
Grignani, G. (Candiolo Cancer Institute) ;
Gronchi, A. (University of Milan) ;
Haas, R.L. (Leiden University Medical Centre) ;
Hassan, B. (Oxford University Hospitals NHS Foundation Trust) ;
Hecker-Nolting, S. (Klinikum Stuttgart-Olgahospital) ;
Hohenberger, P. (Mannheim University Medical Center) ;
Issels, R. (University Munich) ;
Joensuu, H. (Helsinki University Central Hospital (HUCH)) ;
Jones, R.L. (Royal Marsden Hospital (Regne Unit)) ;
Judson, I. (Institute of Cancer Research) ;
Jutte, P. (University Medical Center Groningen) ;
Kaal, S. (Radboud University Medical Center) ;
Kager, L. (St. Medical University Vienna) ;
Kasper, B. (Mannheim University Medical Center) ;
Kopeckova, K. (University Hospital Motol) ;
Krákorová, D.A. (Masaryk Memorial Cancer Institute) ;
Ladenstein, R. (Medical University Vienna) ;
Le Cesne, A. (Gustave Roussy Cancer Campus) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lugowska, I. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Merimsky, O. (Tel Aviv Sourasky Medical Center (Ichilov)) ;
Montemurro, M. (Medical Oncology University Hospital of Lausanne) ;
Morland, B. (Birmingham Women's and Children's NHS Foundation Trust) ;
Pantaleo, M.A. (Policlinico S Orsola-Malpighi Università di Bologna) ;
Piana, R. (University of Turin) ;
Picci, P. (Istituto Ortopedico Rizzoli) ;
Piperno-Neumann, S. (Institut Curie) ;
Reichardt, P. (Helios Klinikum Berlin Buch) ;
Robinson, M.H. (Weston Park Hospital NHS Trust) ;
Rutkowski, P. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Safwat, A.A. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Schöffski, P. (University Hospitals Leuven (Bèlgica)) ;
Sleijfer, S. (Erasmus MC Cancer Institute) ;
Stacchiotti, S. (Istituto Nazionale Dei Tumori) ;
Strauss, S.J. (University College London Hospitals NHS Trust) ;
Sundby Hall, K. (Norwegian Radium Hospital) ;
Unk, M. (Institute of Oncology of Ljubljana) ;
Van Coevorden, F. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Van Der Graaf, W.T.A. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Whelan, J. (Sarcoma Unit. University College London Hospitals NHS Trust) ;
Wardelmann, E. (Universitätsklinikum Münster) ;
Zaikova, O. (Oslo University Hospital (Oslo, Noruega)) ;
Blay, Jean-Yves (Centre Leon Bernard and UCBL1) ;
Universitat Autònoma de Barcelona
2018 -  10.1093/annonc/mdy310
Annals of oncology, Vol. 29 (january 2018) , p. iv79-iv95
|
|
|
2.
|
|
15 p, 1.7 MB |
Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications
/
Carrillo-Reixach, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Torrens, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Simón-Coma, Marina (Institut Germans Trias i Pujol) ;
Royo, Laura (Institut Germans Trias i Pujol) ;
Domingo-Sàbat, Montse (Institut Germans Trias i Pujol) ;
Abril-Fornaguera, Jordi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Akers, N. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica)) ;
Sala Llinas, Margarita (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ragull, Sonia (Institut Germans Trias i Pujol) ;
Arnal, Magdalena (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Villalmanzo, Núria (Institut Germans Trias i Pujol) ;
Cairo, Stefano (Instituto di Ricerca Pediatrica. Corso Stati Uniti 4) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Kappler, R. (Department of Pediatric Surgery. Dr. von Hauner Children's Hospital. Ludwig-Maximilians-University Munich) ;
Garrido-Pontnou, Marta (Hospital Universitari Vall d'Hebron) ;
Guerra, Laura (Hospital Universitario La Paz (Madrid)) ;
Sábado, Constantino (Hospital Universitari Vall d'Hebron) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Piñeyro, David (Institut Germans Trias i Pujol) ;
Vázquez-Vitali, María (Institut Germans Trias i Pujol) ;
Kuchuk, O. (Mount Sinai Liver Cancer Program. Divisions of Liver Diseases. Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ;
Mateos, María Elena (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Ramírez, G. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Santamaría, María (Hospital Universitario La Paz (Madrid)) ;
Mozo, Y. (Hospital Universitario La Paz (Madrid)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Grotzer, M. (Department of Pediatric Oncology. University Children's Hospital Zurich. University of Zurich) ;
Branchereau, S. (Bicêtre Hospital) ;
de Andoin, N. G. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
López-Ibor, B. (Department of Pediatric Hematology and Oncology. HM Montepríncipe Hospital) ;
López-Almaraz, R. (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Salinas, J. A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Torres, B. (Hospital Universitari i Politècnic La Fe (València)) ;
Hernández, Francisco (Hospital Universitario La Paz (Madrid)) ;
Uriz, J. J. (Hospital Universitario de Donostia (Sant Sebastià, País Basc)) ;
Fabre, M. (Department of Pathology. Hôpital Universitaire Necker-Enfants Malades. Assistance Publique-Hôpitaux de Paris. Université Paris Descartes) ;
Blanco, J. (Joan) (Joan) (Universitat de Vic - Universitat Central de Catalunya) ;
Paris, C. (Stem Cell Transplant Unit. Hospital Luis Calvo Mackenna) ;
Bajčiová, V. (Department of Pediatric Oncology. Childrens University Hospital Brno) ;
Laureys, G. (Ghent University Hospital. (Bèlgica)) ;
Masnou, Helena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Clos, Ariadna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Beléndez, Cristina (Hospital General Universitario Gregorio Marañón) ;
Guettier, C. (Bicêtre Hospital) ;
Sumoy, Lauro (Institut Germans Trias i Pujol) ;
Planas, Ramón (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Jordà, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Nonell, Lara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Czauderna, P. (Department of Surgery and Urology for Children and Adolescents. Medical University of Gdansk) ;
Morland, B. (Birmingham Women's Hospital) ;
Sia, D. (Mount Sinai Liver Cancer Program. Divisions of Liver Diseases. Tisch Cancer Institute. Icahn School of Medicine at Mount Sinai) ;
Losic, B. (Icahn Institute for Data Science and Genomic Technology (Nova York, Estats Units d'Amèrica)) ;
Buendia, M. A. (INSERM. UMR 1193. Paul-Brousse Hospital. Hepatobiliary Centre) ;
Sarrias, Maria-Rosa (Institut Germans Trias i Pujol) ;
Llovet, J. M. (Institució Catalana de Recerca i Estudis Avançats) ;
Armengol, Carolina (Institut Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Background & Aims: Hepatoblastoma (HB) is a rare disease. Nevertheless, it is the predominant pediatric liver cancer, with limited therapeutic options for patients with aggressive tumors. Herein, we aimed to uncover the mechanisms of HB pathobiology and to identify new biomarkers and therapeutic targets in a move towards precision medicine for patients with advanced HB. [...]
2020 - 10.1016/j.jhep.2020.03.025
Journal of Hepatology, Vol. 73 Núm. 2 (august 2020) , p. 328-341
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
